Piperacillin-tazobactam-induced drug hypersensitivity syndrome

Cutis

Volumn 77, Issue 6, 2006, Pages 353-357

  Fahim, Simone ^a,c   Jain, Vikas ^b   Victor, Gary ^a   Pierscianowski, Tadeusz ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; DRUG DERIVATIVE; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN TAZOBACTAM COMBINATION PRODUCT; PIPERACILLIN-TAZOBACTAM COMBINATION PRODUCT;

ADULT; CASE REPORT; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; MEDICAL EDUCATION; PATHOPHYSIOLOGY; REVIEW;

ADULT; ANTI-BACTERIAL AGENTS; DRUG HYPERSENSITIVITY; EDUCATION, MEDICAL, CONTINUING; FEMALE; HUMANS; PENICILLANIC ACID; PIPERACILLIN;

EID: 33745844489     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Gentry LO, Rodriguez GG. Oral ciprofloxacin compared with patenteral antibiotics in the treatment of osteomyelitis. Antimicrob Agents Chemother. 1990;34:40-43.
2. Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome in vitro assessment of risk. J Clin Invest. 1988;82:1826-1832.
3. Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS). Semin Cutan Med Surg. 1996;15:250-257.
4. Sontheimer RD, Houpt KR. DIDMOHS: a proposed consensus nomenclature for the drug-induced delayed multiorgan hypersensitivity syndrome [letter]. Arch Dermatol. 1998;134:874-876.
5. Sullivan JR, Shear NH. The drug hypersensitivity syndrome: what is the pathogenesis? Arch Dermatol. 2001;137:357-364.
6. Conilleau V, Dompmartin A, Verneuil L, et al. Hypersensitivity syndrome due to 2 anticonvulsant drugs. Contact Dermatitis. 1999;3:141-144.
7. Knowles SR, Shapiro LE, Shear NH. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. Drug Saf. 1999;21:489-501.
8. Queyrel V, Catteau B, Michon-Pasteurel U, et al. DRESS (drug rash with eosinophilia and systemic symptoms) syndrome after sulfasalazine and carbamazepine: report of two cases [in French]. Rev Med Interne. 2001;22: 582-586.
9. Mainra RR, Card SE. Trimethoprim-sulfamethoxazole associated hepatotoxicity part of a hypersensitivity syndrome. Can J Clin Pharmacol. 2003;10:175-178.
10. Sarris BM, Wong JG. Multisystem hypersensitivity reaction to lamotrigine. Neurology. 1999;53:1367.
11. Muller P, Dubreil P, Mahe A, et al. Drug hypersensitivity syndrome in a West-Indian population. Eur J Dermatol. 2003;13:478-481.
12. Lupton JR, Figueroa P, Tamjidi P, et al. An infectious mononucleosis-like syndrome induced by minocycline: a third pattern of adverse drug reaction. Cutis. 1999;64:9-16.
13. Carpenter C. Allopurinol hypersensitivity syndrome. Tenn Med. 1997;90:151-152.
14. Arellano F, Sacristan JA. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother. 1993;27:337-343.
15. Lanzafame M, Rovere P, De Checchi G, et al. Hypersensitivity syndrome (DRESS) and meningoencephalitis associated with nevirapine therapy. Scand J Infect Dis. 2001;33:475-476.
16. Huang YL, Hong HS, Wang ZW, et al. Fatal sodium valproate-induced hypersensitivity syndrome with lichenoid dermatitis and fulminant hepatitis. J Am Acad Dermatol. 2003;49:316-319.
17. Shear N, Spielberg S, Grant DM, et al. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med. 1986;105:179-184.
18. Messenheimer J, Mullens EL, Giorgi L, et al. Safety review of adult clinical trial experience with lamotrigine. Drug Saf. 1998;18:281-296.
19. Shapiro LE, Shear NH. Mechanisms of drug reactions: the metabolic track. Semin Cutan Med Surg. 1996;15: 217-227.
20. Ohtani T, Hiroi A, Sakurane M, et al. Slow acetylator genotypes as a possible risk factor for infectious mononucleosis-like syndrome induced by sulfapyridine. Br J Dermatol. 2003;148:1035-1039.
21. Knowles S, Shapiro L, Sheir NH. Should celecoxib be contraindicated in patients who are allergic to sulfonamides. revisiting the meaning of 'sulfa' allergy. Drug Saf. 2001;24:239-247.
22. Descamps V, Valence A, Edlinger C, et al. Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms. Arch Dermatol. 2001;137:301-304.
23. Hashimoto K, Yasukawa M, Tohyama M. Human herpesvirus 6 and drug allergy. Curr Opin Allergy Clin Immunol. 2003;3:255-260.
24. Condat B, Zanditenas D, Collot V, et al. A new cause of intra and extrahepatic cholangitis: the drug hypersensitivity syndrome or DRESS. Gastroenterol Clin Biol. 2006;30:142-146.
25. Levy M. Role of viral infections in the induction of adverse drug reactions. Drug Saf. 1997;16:1-8.
26. Choquet-Kastylevsky G, Intrator L, Chenal C, et al. Increased levels of interleukin 5 are associated with the generation of eosinophilia in drug-induced hypersensitivity syndrome. Br J Dermatol. 1998;139:1026-1032.
27. Daniel KP, Krop LC. Piperacillin-tazobactam: a new beta-lactam-beta- lactamase inhibitor combination. Pharmacotherapy. 1996;16:149-162.
28. Gerber L, Wing EJ. Life-threatening neutropenia secondary to piperacillin tazobactam therapy. Clin Infect Dis. 1995;21:1047-1048.
29. Ruiz-Irastorza G, Barreiro G, Aguirre C. Reversible bone marrow depression by high dose piperacillin/tazobactam. Br J Haematol. 1996;95:611-612.
30. Soto J, Bosch JM, Alsar Ortiz MJ, et al. Piperacillin-induced acute interstitial nephritis. Nephron. 1993;65: 154-155.
31. Pill MW, O'Neill CV, Chapman MM, et al. Suspected acute interstitial nephritis induced by piperacillin-tazobactam. Pharmacotherapy. 1997;17:166-169.
32. Park-Matsumoto YC, Tazawa T. Piperacillin-induced encephalopathy. J Neurol Sci. 1996;140:141-142.
33. Mackie K, Pavlin EG. Recurrent paralysis following piperacillin administration. Anesthesiology. 1990;72: 561-563.
34. Mead GM, Smith AG. Allergic skin reactions to piperacillin in patients with acute leukemia [letter]. Lancet. 1985;2:499.
35. Joy VA. Piperacillin and haemorrhagic cystitis [letter]. Lancet. 1979;1:219.
36. Behbahani R, Kostman JR. Hypersensitivity reaction during prolonged use of piperacillin/tazobactam in treatment of osteomyelitis [letter]. Ann Pharmacother. 1995;29:936-937.
37. Ghislain PD, Roujeau JC. Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J. 2002;8(1):5.